1
|
Riou M, Oulehri W, Momas C, Rouyer O, Lebourg F, Meyer A, Enache I, Pistea C, Charloux A, Marcot C, de Blay F, Collange O, Mertes M, Andrès E, Talha S, Geny B. Reduced Flow-Mediated Dilatation Is Not Related to COVID-19 Severity Three Months after Hospitalization for SARS-CoV-2 Infection. J Clin Med 2021; 10:jcm10061318. [PMID: 33806800 PMCID: PMC8004847 DOI: 10.3390/jcm10061318] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 03/16/2021] [Accepted: 03/18/2021] [Indexed: 01/12/2023] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly worldwide, with more than two million deaths. Evidence indicates the critical role of the vascular endothelium in its pathophysiology but, like potential changes in functional vasodilation, the vascular effect of SARS-CoV-2 at a given distance from the acute infection is largely unknown. We assessed brachial artery flow-mediated dilatation (FMD) in 27 COVID-19 patients needing conventional or intensive care unit hospitalization, three months after SARS-CoV-2 infection diagnosis and in nine age- and sex- matched control subjects. Interestingly, the FMD was lower in COVID-19 patients as compared to controls (8.2 (7.2–8.9) vs. 10.3 (9.1–11.7)); p = 0.002, and half of the hospitalized COVID-19 survivors presented with a reduced FMD < 8% at three months of COVID-19 onset. Impaired FMD was not associated with severe or critical SARS-CoV-2 infection, reflected by ICU hospitalization, total hospitalization duration, or severity of lung damage. In conclusion, reduced FMD is often observed even three months after hospitalization for SARS-CoV-2 infection, but such alteration predominantly appears to not be related to COVID-19 severity. Longer and larger follow-up studies will help to clarify the potential prognosis value of FMD among COVID-19 patients, as well as to further determine the mechanisms involved.
Collapse
Affiliation(s)
- Marianne Riou
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Walid Oulehri
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Department of Anesthesiology and Surgical Critical Care, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, France
| | - Cedric Momas
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Olivier Rouyer
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Fabienne Lebourg
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Alain Meyer
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Irina Enache
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Cristina Pistea
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Anne Charloux
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Christophe Marcot
- Department of Pneumology, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, France;
| | - Frederic de Blay
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Department of Pneumology, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, France;
| | - Olivier Collange
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Department of Anesthesiology and Surgical Critical Care, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, France
| | - Michel Mertes
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Department of Anesthesiology and Surgical Critical Care, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, France
| | - Emmanuel Andrès
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Department of Internal Medicine, University Hospital of Strasbourg, 1 Place de l’hôpital, 67091 Strasbourg, France
| | - Samy Talha
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
| | - Bernard Geny
- Team 3072 “Mitochondria, Oxidative Stress and Muscle Protection”, Unistra, Faculty of Medicine, Translational Medicine Federation of Strasbourg (FMTS), University of Strasbourg, 11 rue Humann, 67000 Strasbourg, France; (M.R.); (W.O.); (O.R.); (A.M.); (I.E.); (C.P.); (A.C.); (F.d.B.); (O.C.); (M.M.); (E.A.); (S.T.)
- Physiology and Functional Exploration Service, University Hospital of Strasbourg, CHU, 1 Place de l’hôpital, 67091 Strasbourg, France; (C.M.); (F.L.)
- Correspondence:
| |
Collapse
|
2
|
Effects of a High Fat Meal Associated with Water, Juice, or Champagne Consumption on Endothelial Function and Markers of Oxidative Stress and Inflammation in Young, Healthy Subjects. J Clin Med 2019; 8:jcm8060859. [PMID: 31208093 PMCID: PMC6617404 DOI: 10.3390/jcm8060859] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 05/31/2019] [Accepted: 06/12/2019] [Indexed: 12/19/2022] Open
Abstract
Endothelial dysfunction (ED), often linked to hypertriglyceridemia, is an early step of atherosclerosis. We investigated, in a randomized cross-over study, whether high-fat meal (HFM)-induced ED might be reduced by fruit juice or champagne containing polyphenols. Flow-mediated dilatation (FMD) and biological parameters (lipid profile, glycemia, inflammation, and oxidative stress markers) were determined before and two and three hours after the HFM in 17 healthy young subjects (24.6 ± 0.9 years) drinking water, juice, or champagne. Considering the entire group, despite significant hypertriglyceridemia (from 0.77 ± 0.07 to 1.41 ± 0.18 mmol/L, p < 0.001) and a decrease in Low Density Lipoprotein (LDL), the FMD was not impaired. However, the FMD decreased in 10 subjects (from 10.73 ± 0.95 to 8.13 ± 0.86 and 8.07 ± 1.16%; p < 0.05 and p < 0.01; 2 and 3 h, respectively, after the HFM), without concomitant change in concentration reactive protein or reactive oxygen species, but with an increase in glycemia. In the same subjects, the FMD did not decrease when drinking juice or champagne. In conclusion, HFM can impair the endothelial function in healthy young subjects. Fruit juice, rich in anthocyanins and procyanidins, or champagne, rich in simple phenolic acids, might reduce such alterations, but further studies are needed to determine the underlying mechanisms, likely involving polyphenols.
Collapse
|
3
|
Fussner LA, Heimbach JK, Fan C, Dierkhising R, Coss E, Leise MD, Watt KD. Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk. Liver Transpl 2015; 21:889-96. [PMID: 25880971 DOI: 10.1002/lt.24137] [Citation(s) in RCA: 135] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Revised: 03/09/2015] [Accepted: 03/22/2015] [Indexed: 12/11/2022]
Abstract
The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity and metabolic syndrome (MS), define the cumulative incidence of CVD, and characterize risk factors associated with these comorbidities after LT. A retrospective review of 455 consecutive LT recipients from 1999 to 2004 with an 8- to 12-year follow-up was performed. Obesity increased from 23.8% (4 months) to 40.8% (3 years) after LT. Increase in body mass index predicted MS at 1 year after LT (odds ratio, 1.1; P < 0.001, per point). CVD developed in 10.6%, 20.7%, and 30.3% of recipients within 1, 5, and 8 years, respectively. Age, diabetes, hypertension, glomerular filtration rate < 60 mL/minute, prior CVD, ejection fraction < 60%, left ventricular hypertrophy, and serum troponin (TN) > 0.07 ng/mL were associated with CVD on univariate analysis. Age (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.01-1.06; P = 0.019), diabetes (HR, 1.78; 95% CI, 1.09-2.92; P = 0.022), prior history of CVD (HR, 2.46; 95% CI, 1.45-4.16; P < 0.001), and serum TN > 0.07 ng/mL (HR, 1.98; 95% CI, 1.23-3.18; P = 0.005) were independently associated with CVD in the long term. Smoking history (ever), sex, hyperlipidemia, and serum ferritin levels were not predictive of CVD. Tacrolimus use versus noncalcineurin-based immunosuppression (HR, 0.26; 95% CI, 0.14-0.49; P < 0.001) was associated with reduced risk of CVD but not versus cyclosporine (HR, 0.67; 95% CI, 0.30-1.49; P = 0.322). CVD is common after LT. Independent of MS, more data are needed to identify nonconventional risk factors and biomarkers like serum TN. Curbing weight gain in the early months after transplant may impact MS and subsequent CVD in the long term.
Collapse
Affiliation(s)
- Lynn A Fussner
- Department of Internal Medicine, Transplant Center, Mayo Clinic, Rochester, MN
| | | | - Chun Fan
- Division of Biomedical Statistics and Informatics, Transplant Center, Mayo Clinic, Rochester, MN
| | - Ross Dierkhising
- Division of Biomedical Statistics and Informatics, Transplant Center, Mayo Clinic, Rochester, MN
| | - Elizabeth Coss
- Department of Internal Medicine, Transplant Center, Mayo Clinic, Rochester, MN
| | - Michael D Leise
- Department of Internal Medicine, Transplant Center, Mayo Clinic, Rochester, MN.,Gastroenterology and Hepatology, Transplant Center, Mayo Clinic, Rochester, MN
| | - Kymberly D Watt
- Department of Internal Medicine, Transplant Center, Mayo Clinic, Rochester, MN.,Gastroenterology and Hepatology, Transplant Center, Mayo Clinic, Rochester, MN
| |
Collapse
|